Feb 12, 2020
TB Alliance Names Dr. Daniel Everitt Vice President and Chief Medical Officer
Jan 31, 2020
Immunitor unveils breakthrough immunotherapy to treat tuberculosis in as short as one month
Aug 14, 2019
FDA Approves Breakthrough Drug to Treat Extensively Drug-Resistant Tuberculosis
May 20, 2019
New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease
Apr 18, 2019
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB)
Aug 24, 2018
Global Tuberculosis (TB) Drugs/Therapeutics Market, 2018-2025 - Key Players are J&J Services, Lupin, Pfizer, Novartis, Macleods Pharmaceuticals, and Otsuka Pharmaceutical
Jul 18, 2018
TB Drugs Market Size Worth $1.38 Billion by 2025 | CAGR: 5.2%: Grand View Research, Inc.
Jul 13, 2018
TB Alliance Names Angela Vanderploeg as Chief Financial Officer
Jul 04, 2018
The global tuberculosis drugs/therapeutics (TB) market size is expected to reach USD 1.38 billion by 2025
May 24, 2018
The Medicines Patent Pool Presents New Five-Year Strategy for Improving Access to Priority Treatments in Developing Countries
Mar 23, 2018
The Government of Canada and Inuit Tapiriit Kanatami commit to eliminating tuberculosis across Inuit Nunangat by 2030
Mar 06, 2018
Nancy Miller-Rich Joins TB Alliance Board of Directors
Aug 24, 2017
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba(TM)) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries